The global Oral Mucositis Market size is expected to register 7.1% CAGR during the forecast period of 2019 to 2025, with a market value of USD 2,247 million in 2018. Oral mucositis is an acute inflammation or ulceration of the oral or oropharyngeal mucosal membranes. It can cause pain/discomfort, interfere with swallowing, eating, and speech, and may lead to infection. The global oral mucositis market is driven by factors such as rising incidences of cancer globally and increasing oral mucositis drug development. For instance, according to the National Center for Biotechnology Information, oral mucositis occurs in up to 40% of cancer patients that receive chemotherapy and approaches 100% in the treatment of head and neck cancers. Additionally, according to National Cancer Institute, an estimated 1,735,350 new cases of cancer were diagnosed in the US in 2018. Furthermore, according to the US Department of Health and Human Services, the prevalence of cancer in the US is 439.2 per 100,000 men and women. Moreover, according to WHO, there are 3.7 million cases of cancer in Europe every year. On the other hand, most of the drugs are not to be ingested, which restricts their usage for oral mucositis is projected to hamper the growth of the market during the assessment period. Moreover, major companies in the market are involved in strategic acquisitions, collaborations, and mergers, and receive new patents to sustain their position in the market. For instance, in February 2019, Innovation Pharmaceuticals receives new patent for compounds for use in treatment of oral mucositis. The patent covers methods for treating and/or preventing mucositis with one or more compounds, or pharmaceutically acceptable salts.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1531
Oral Mucositis Market Segmentation
The global oral mucositis market has been segmented based on cause, end user, and region.
The market, based on cause, has been bifurcated into oral mucositis caused by chemotherapy, oral mucositis caused by radiotherapy, and oral mucositis caused by hematopoietic stem cell transplantation
The global market, based on end user, has been segmented into hospitals, dental clinics, oncology hospitals, and research institutes. Based on cause, the oral mucositis caused by chemotherapy segment is expected to hold a major share in the market as chemotherapy is widely used as a treatment method for cancer. For example, according to the US Department of Health & Human Services, every year, about 650,000 cancer patients receive chemotherapy in an outpatient oncology clinic in the US. Based on end user, the hospitals segment is expected to hold a major share in the market due to its close association with cancer availability of all possible treatment options.
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The oral mucositis market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European oral mucositis market has been sub-divided into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The oral mucositis market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The oral mucositis market in the Middle East & Africa has been divided into the Middle East and Africa.
Global Oral Mucositis Market, by Cause
- Oral Mucositis Caused by Chemotherapy
- Oral Mucositis Caused by Radiotherapy
- Oral Mucositis Caused by Hematopoietic Stem Cell Transplantation
Global Oral Mucositis Market, by End User
- Hospitals
- Dental Clinics
- Oncology Hospitals
- Research Institutes
Key Players
The key players operating in the global oral mucositis market are Izun Pharmaceuticals Corporation, Shoreline Pharmaceuticals, Inc, AMAG Pharmaceutical Inc, Innovation Pharmaceuticals, The Himalaya Drug Company, Access pharmaceuticals, EKR therapeutics Inc, EUSA Pharma Inc, Swedish Orphan Biovitrum AB (publ), Soligenix, and Daewoong Co. Ltd.
Regional Market Summary:
Source: World Health Organization (WHO) The market in the Americas is expected to dominate the oral mucositis market due to the increasing incidences of head and neck cancers. For example, according to the American Society of Clinical Oncology (ASCO), head and neck cancer account for about 4% of all cancers in the US. In 2019, an estimated 65,410 people will develop head and neck cancer. High cases of cancer in the US and Canada is expected to drive the market growth. Furthermore, increasing expenses in research by healthcare bodies engaged in improving oral mucositis treatment are the factors contributing to its largest share is expected to fuel the growth of the market in this region. The market in Europe showed a considerable amount of growth. This can be attributed to the presence of a well-established healthcare system, an increase in cancer diseases, and the involvement of key companies. For instance, in April 2016, EUSA Pharma announces the acquisition of global rights to next-generation oncology supportive care product Arcoral Tab from Arcoral Pharma. The market in Asia-Pacific is projected to have a steady growth rate during the forecast period owing to the increasing prevalence of cancer and increasing government initiatives for healthcare reforms. The market in the Middle East & Africa is projected to account for the least share of the global market due to low per capita disposable income in the region.
Browse more details of Report @ https://www.marketresearchfuture.com/reports/oral-mucositis-market-1531
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: [email protected]
Growth in this market is driven by the growing pharmaceutical industry in Latin American countries such as Brazil, Mexico, and Argentina; increasing focus of MNCs on investing in the pharmaceutical and healthcare sectors in Latin America; growing pricing pressures; rapid growth in aging population & the subsequent increase in the prevalence of related diseases; and the availability of local and government funding for R activities.The Latin America Pharmaceutical Excipients Market is projected to reach USD 579 million by 2024 from USD 403 million in 2019, at a CAGR of 7.5%.Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=41302221Market Segmentation:- The Latin America pharmaceutical excipients market, by functionality, is segmented into fillers & diluents, binders, suspending & viscosity agents, flavoring agents & sweeteners, coating agents, colorants, disintegrants, lubricants & glidants, preservatives, emulsifiers & solubilizers, and other functionalities.
The fillers & diluents segment accounted for the largest market share in 2018.
The increased use of fillers & diluents in the development and production of solid dosage form and the wide applications of diluents in the wet granulation and direct compression process for tablet formulation are driving the growth of the fillers & diluents segment.Recent Developments:-In 2018, Roquette launched the carbohydrate-based excipients—Maize Starch IP/BP and Mannitol IP.In 2017, DuPont acquired FMC Corporation’s Health & Nutrition business except for the Omega-3 business.
With this acquisition, FMC’s Health & Nutrition segment will be integrated into the DuPont Nutrition & Health segment.
It extends DuPont’s capabilities into the fast-growing pharma excipients space.In 2016, BASF signed an agreement with Colorcon (US) to sell its Kollicoat IR Coating Systems product line to Colorcon.
This enabled the company to focus on its core competencies.
The global Temperature Sensors market is expected to witness a high growth in the coming years.
Moreover, the increasing focus on workplace safety is driving the deployment of Temperature Sensors for work floor monitoring.
However, in 2016, the top six players commanded less than 20% of the Covid 19 Analysis on Temperature Sensors Market.
These players are aiming at improving research and development facilities along with continuous innovation to introduce sensors that are in line with the changing requirements of end-use industries.The Temperature Sensors Market is growing rapidly over 4.8% of CAGR and is expected to reach at USD $~5.93 Billion by the end of forecast period.Taste the market data and market information presented through more than 30 market data tables and figures spread over 100 numbers of pages of the project report.
By product type, the market is divided into thermocouples, bimetallic Temperature Sensors, infrared Temperature Sensors, thermistors, fiber optic Temperature Sensors, non-contact sensors, Temperature Sensors ICs, resistive temperature detectors, and others.
By regions, it is segmented into North America, Europe, APAC, and rest of the world.Key Players:The prominent players in the Temperature Sensors Market are – Siemens A G (Germany), Stmicroelectronics N.V. (Switzerland), TE Connectivity (Switzerland), Ultra Electronics Holdings Plc.
